within 30 days after the PCI procedure, and 114 (74%) events occurred in the setting of STEMI. Out of all the deaths, pre-procedural cardiogenic shock, cardiac arrest, CHF, and sustained ventricular tachycardia, were present in 48%, 31%, 29%, and 7% patients, respectively. Overall, only 42 (27%) patients died from PCI-related events, and the majority of these were related to definite (5%) or presumed (15%) subacute stent thrombosis. The most common cause of mortality was non-PCI-related cardiac death (73 patients, 47%), with post-STEMI cardiogenic shock (36%) being the most common etiology. Forty-four patients (28%) died from non-cardiac-related causes, and anoxic encephalopathy (16%) after cardiac arrest complicating STEMI was the most common cause in this category. Conclusions: The majority of the deaths after PCI in a regional cardiac centre were related to the patients' presenting illnesses and comorbidities, rather than PCI-related causes, which would be a better marker of PCI quality.
Background: The MGuard Stent (MGS) was designed to prevent distal embolisation of thrombus and has been shown to improve microcirculation in ST-elevation myocardial infarction (STEMI). However, there are no real world data comparing it with the bare metal stent (BMS). The aim of this study is to determine the efficacy and safety of the MGS in STEMI in the real world compared to the BMS. Methods: All STEMI patients undergoing primary angioplasty between July 2011 and January 2013 were included in the study except patients with cardiogenic shock (Killip IV) or those in which the DES was implanted. In total, 262 patients were included from a single centre, of which 35.9% had an MGS implanted. Two groups of 79 patients were established after propensity score matching (PSM), and they were similar in terms of baseline and periprocedural variables. Results: The mean follow-up was 321 AE 12.94 days. There was no difference in mortality (7.6% in both groups), major adverse cardiac events (MACE) (20.3% vs. 12.7%, P ¼ 0.198), non-cardiac mortality or non-fatal myocardial infarction (6.3% in both groups). Target lesion revascularisation (TLR) was significantly higher in the MGS group (11.4% (9) vs. 1.3% (1) P < 0.01; RR 10.02 [1.23 to 81.16]) (Table 1) .
Conclusions: Our study is the first to compare the MGS with the BMS in STEMI in the real world, and it also appears to confirm that although the MGS is a safe device in STEMI that is not associated with increased mortality, it is associated with a higher long-term TLR rate. Hartford Hospital, Hartford, CT Background: Patients with ST elevation myocardial infarction (STEMI) who are transferred for primary PCI from a non-PCI facility have longer reperfusion times which may be associated with poorer clinical outcomes. The aim of this study was to compare in hospital clinical outcomes among patients presenting directly to a PCI facility (Non Transfer STEMI group) with those transferred from non-PCI facility for primary PCI (Transfer STEMI group). Methods: A retrospective analysis of patients undergoing primary PCI for acute STEMI from July 2009 to Dec 2013 at a tertiary care PCI hospital was performed. Patients were identified as Non Transfer STEMI (n¼501) and Transfer STEMI (n¼507). Demographic characteristics, risk factors and in hospital clinical outcomes were compared between the two groups. Results: The basic demographic profiles and cardiovascular risk factors were very similar between the two groups. The percentage of patients who presented with cardiogenic shock and/or cardiac arrest in both groups was similar (12.8% vs 14.4% respectively, p¼0.45). The goal door to balloon time (DTB) was achieved in 85% of patients in Non-Transfer STEMI (< 90 min) group and 33% of patients in Transfer STEMI group (< 120 min). 38% of patients in the transfer STEMI group had DTB time between 120 to 180 minutes. Occurrence of Post PCI cardiogenic shock, CHF and stroke was similar between the 2 groups. The all cause in hospital mortality was similar in Non Transfer STEMI vs Transfer STEMI group (5.2% vs 5.3%, p¼0.9) 
